Evaluating Liposomal Bupivacaine Plus Bupivacaine for Pain Relief After Laparoscopic Surgery in Gynecologic Oncology Patients

What this Trial Is About

Researchers are evaluating the use of liposomal bupivacaine combined with bupivacaine for managing postoperative pain in patients undergoing laparoscopic surgery for gynecologic oncology. Laparoscopic surgery is minimally invasive and allows for faster recovery and shorter hospital stays. However, the procedure can cause diaphragm elevation and increased abdominal pressure, leading to systemic inflammation and postoperative pain. This study aims to assess the safety and effectiveness of this analgesic approach compared to standard treatment. The study compares two groups one receiving a bilateral transversus abdominis plane block TAPB with bupivacaine hydrochloride, and the other receiving TAPB with a mixture of liposomal bupivacaine and bupivacaine. Both procedures use ultrasound guidance before surgery. Postoperatively, patients use a patient-controlled analgesia pump with sufentanil and ondansetron and may take oral oxycodone-acetaminophen or intravenous morphine if needed. The study uses a randomized, quadruple-masked design. Participants will be monitored for pain levels at rest and during movement at intervals up to three months after surgery using the numeric rating scale. Researchers will track opioid use, time to first analgesia request, sedation, patient satisfaction, recovery quality, hospital stay length, complications, and adverse events. The study starts in March 2026 and ends in June 2027, with detailed postoperative and follow-up assessments to evaluate outcomes and safety.

The Efficacy and Safety of Liposomal Bupivacaine for Transversus Abdominis Plane Block in Relieving Postoperative Pain After Laparoscopic Surgery in Gynecologic Oncology